Healthcare / BiotechnologyNYSE
$8.93
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-336.3M · quality 56.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
0/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$583M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-61.5%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
+21.0%
FCF CAGR
—
FCF margin
-105.0%
FCF / Net income
0.57x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $170.2M · net income $-312.8M · FCF $-178.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $170.2M | $170.2M | $227.0M | $251.5M | $477.7M | $313.8M | $76.7M | $54.2M |
| Net Income | $-312.8M | $-312.8M | $-547.0M | $-892.9M | $-2.10B | $-1.83B | $-126.6M | $-119.3M |
| EBITDA | $-256.3M | $-256.3M | $-496.7M | $-793.9M | $-2.17B | $-1.80B | $-123.2M | $-60.8M |
| EPS | -5.64 | -5.64 | -10.54 | -18.37 | -50.20 | -1.39 | -0.10 | -0.10 |
| Operating Margin | -185.3% | -185.3% | -246.5% | -343.8% | -462.4% | -582.6% | -178.8% | -132.1% |
| Net Margin | -183.8% | -183.8% | -240.9% | -355.1% | -440.6% | -583.1% | -165.2% | -220.2% |
| Cash Flow | ||||||||
| Free Cash Flow | $-178.7M | $-178.7M | $-382.1M | $-336.3M | $-304.5M | $-310.3M | $-193.7M | $-66.9M |
| Returns | ||||||||
| ROE | -61.5% | -61.5% | -76.4% | -81.4% | -121.2% | -121.6% | -27.4% | — |
| Growth & Yield | ||||||||
| Revenue Growth | -25.1% | -25.1% | -9.7% | -47.4% | 52.2% | 309.4% | 41.5% | — |
| EPS Growth | 46.5% | 46.5% | 42.6% | 63.4% | -3511.5% | -1290.0% | 0.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.